1. South Korea Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
ORIENT BIO Inc.

ORIENT BIO Inc.

002630.KS
ORIENT BIO Inc.KR flagKorea Exchange
882.00
KRW
+23.00
- -
52.30BMarket Cap
ORIENT BIO Inc.
002630.KS
(Korea Exchange)

Recent

price

882.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
2,203.04
2,358.67
3,417.49
3,518.35
3,583.71
3,171.65
2,986.72
687.65
783.04
719.71
918.88
442.57
487.13
474.33
494.61
- -
501.89
Revenue per Share
185.97
-480.41
30
-401.36
-66.89
-90.86
-536.48
-372.07
-502.87
-232
-276.15
576
-210
218
-222
- -
-77.03
Basic EPS, GAAP
-81.35
-440.09
-702.4
-422.91
-216.89
-482.47
-321.59
-149.18
-772.64
-111.92
149.85
2.37
11.4
47.95
-67.91
- -
9.24
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
1,045.79
165.88
230.05
1,591.61
1,385.15
2,076.34
1,249.14
1,138.69
1,364.56
839.49
698.7
1,238.24
1,043.37
1,277.05
1,044.53
- -
991.4
Book Value per Share
2,607.37
2,122.38
2,092.37
2,046.8
1,937.01
1,984.65
2,128.29
1,859.83
1,546.82
973.73
849.11
1,393.21
1,202.07
1,439.29
1,207.13
- -
1,154.77
Tangible Book Value per Share
22
22
23
24
26
33
37
37
39
52
57
59
59
59
59
- -
59
Basic Weighted Avg Shares
48,171
52,053
76,980
83,722
93,709
105,050
109,019
25,625
30,373
37,214
52,020
26,276
28,819
28,005
29,398
29,754
29,754
Sales/Revenue/Turnover
-6.21
0.81
4.21
-2.15
0.96
0.11
-8.94
-30.89
-30.4
-33.22
3.57
-14.39
12.02
15.91
-10.46
-13.89
-13.89
Operating Margin (%)
3,821
2,205
2,654
4,177
6,230
5,508
6,665
7,296
8,078
4,918
4,691
3,926
3,090
2,684
1,955
2,205
2,205
Depreciation Expense
4,066
-10,602
676
-9,551
-1,749
-3,009
-19,582
-13,865
-19,506
-11,996
-15,634
34,198
-12,424
12,871
-13,195
-4,567
-4,567
Net Income, GAAP
- -
- -
11.16
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
8.44
-20.37
0.88
-11.41
-1.87
-2.86
-17.96
-54.11
-64.22
-32.24
-30.05
130.15
-43.11
45.96
-44.88
-15.35
-15.35
Profit Margin (%)
32,908
26,681
8,222
858
-2,916
3,948
20,672
5,386
17,417
10,196
13,830
56,854
45,357
54,777
43,204
38,346
38,346
Working Capital
980
12,015
10,309
11,730
8,263
10,110
10,423
12,233
49
3,820
1,095
1,930
168
2,437
1,941
1,211
1,211
LT Debt
65,488
60,515
62,290
61,846
67,350
91,290
91,195
79,923
62,646
52,558
48,545
83,188
71,392
85,096
71,847
68,544
68,544
Total Equity
- -
- -
2.56
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
5.79
- -
- -
- -
Return on Invested Capital (%)
- -
- -
5.38
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
18.34
- -
- -
- -
Return on Capital (%)
19.52
-79.93
15.28
-44.36
-4.72
-5.73
-34.24
-31.5
-40.91
-24.9
-37.69
60.49
-18.37
18.77
-19.2
-7.56
-7.56
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
682
729
725
LT Borrowings
- -
- -
- -
LT Finance Leases
1,621
1,398
1,211
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
59
59
59
Market Capitalization
68,301
71,260
68,533

Working Capital

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
44,680
45,692
43,965
Cash, Cash Equivalents & STI
31,654
33,670
32,772
Accounts Receivable, Net
5,325
5,793
6,571
Inventories
3,637
2,590
2,437
Total Current Liabilities
3,761
3,990
5,619
Payables & Accruals
- -
- -
- -
ST Debt
682
729
725
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-0.16%
11.24%
-4.6%
Free Cash Flow
27.79%
49.06%
-113.54%
Net Income, GAAP
-37.26%
-185.32%
-65.39%
Sales/Revenue/Turnover
-2.83%
-7.29%
1.21%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
7,022
6,411
8,184
6,388
28,005
2025
7,384
6,731
8,957
6,325
29,398
2026
7,681
6,931
8,601
6,541
29,754

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
40
-10
4
- -
218
2025
-114
-18
-22
- -
-222
2026
-34.27
-2.55
-32.37
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
DaShenLin Pharmaceutical Group Co., Ltd. (603233.SS)
Ensysce Biosciences, Inc. (ENSCW)
Psyence Biomedical Ltd. Warrant (PBMWW)
Alaunos Therapeutics, Inc. (TCRT)
Tharimmune, Inc. (THAR)
XORTX Therapeutics Inc. (XRTX)
Business
ORIENT BIO Inc. (002630.KS) operates as a biotechnology company primarily engaged in the production and supply of laboratory animals, including mice, rats, guinea pigs, hamsters, specific pathogen free rabbits and beagles; contract research organization services encompassing safety assessment, new drug development, health checking, genetic testing, molecular biological genetic testing, genetic transformation and phenotyping; research environment equipment and infrastructural solutions; and related products such as specific pathogen free eggs, feeds, reagents and disinfectants. The company serves universities, hospitals, research institutions and biopharma customers in the life sciences and pharmaceutical sectors. Founded in 1959 and headquartered in Seongnam-si, South Korea, ORIENT BIO conducts operations domestically and internationally. In a recent capital-raising move, ORIENT BIO announces plans to sell 9.4 billion won of treasury shares, reflecting ongoing efforts to strengthen its financial position amid bio-industry dynamics. The company previously divested its U.S. subsidiary Orient BioResource Center Inc. to Inotiv Inc. in late 2021 for $51.3 million to focus core competencies, maintaining 125 employees under CEO Jae-Jin Chang.